Innovex International, Inc. Announces Pricing of Underwritten Offering of 5,000,000 Shares of Common Stock by Selling Stockholders
Innovex International, Inc. (NYSE: INVX) (“Innovex” or the “Company”) today announced the pricing of an underwritten offering (the “Offering”) of 5,000,000 shares of its common stock by certain affiliates of Amberjack Capital Partners, L.P. (the “Selling Stockholders”). Innovex will not sell any shares of its common stock in the Offering and will not receive any proceeds from the sale of the shares of its common stock being offered by the Selling Stockholders. The Offering is expected to close on August 10, 2026, subject to customary closing conditions.
The underwriter intends to offer the shares from time to time for sale in one or more transactions on the New York Stock Exchange, in the over-the-counter market, through negotiated transactions or otherwise at market prices prevailing at the time of sale, at prices related to prevailing market prices or at negotiated prices.
Barclays is acting as the sole underwriter for the Offering. The Offering is being made only by means of a prospectus supplement and the accompanying base prospectus, which was filed as part of a shelf registration statement on Form S-3 (File No. 333-282178), which was filed with the Securities and Exchange Commission (the “SEC”) on September 17, 2024, and became effective on October 1, 2024. Before you invest, you should read the prospectus in that registration statement and other documents the Company has filed with the SEC for more complete information about the Company and the Offering. Copies of the preliminary prospectus supplement and accompanying base prospectus relating to the Offering, as well as copies of the final prospectus supplement once available, may be obtained for free on the SEC’s website at www.sec.gov or by contacting: Barclays Capital Inc. c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at barclaysprospectus@broadridge.com.
